Unknown

Dataset Information

0

Hartmann2016 - Blood coagulation model for simulating anticoagulants


ABSTRACT: Mathematical model of blood coagulation. Reused Wajima2009 model with modifications to reactions 27 (formation of Va:Xa complex), 32 (Xa inhibition by TFPI) and 45 (Xa inhibition by TFPI-Heparin complex) as described in publication equations 2,3 and 4. Publication lists parameter sets to simulate Rivaroxaban, VKA and Enoxaparin (supplementary files).

ORGANISM(S): Homo sapiens

SUBMITTER: Matthew Roberts 

PROVIDER: MODEL1807180004 | biostudies-other |

SECONDARY ACCESSION(S): 27647667

REPOSITORIES: biostudies-other

altmetric image

Publications

Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network.

Hartmann S S   Biliouris K K   Lesko L J LJ   Nowak-Göttl U U   Trame M N MN  

CPT: pharmacometrics & systems pharmacology 20160920 10


Warfarin is the anticoagulant of choice for venous thromboembolism (VTE) treatment, although its suppression of the endogenous clot-dissolution complex APC:PS may ultimately lead to longer time-to-clot dissolution profiles, resulting in increased risk of re-thrombosis. This detrimental effect might not occur during VTE treatment using other anticoagulants, such as rivaroxaban or enoxaparin, given their different mechanisms of action within the coagulation network. A quantitative systems pharmaco  ...[more]

Similar Datasets

| MODEL1807230003 | biostudies-other
| MODEL1806270001 | biostudies-other
| MODEL1805140001 | biostudies-other
| MODEL1807180005 | biostudies-other
| MODEL1806060001 | biostudies-other
| MODEL1907120001 | biostudies-other
| MODEL1808160002 | biostudies-other
| MODEL1807230001 | biostudies-other
| MODEL1806250001 | biostudies-other
| S-EPMC8249411 | biostudies-literature